Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Corsica Health vs Spry

Corsica Health
Graded #188

Higher grade

vs+9.5
Spry
Graded #408

Lower grade

The verdict

Corsica Health takes it — 66.3/100 to 56.8/100.

Corsica Health grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Corsica Health is a telehealth platform offering both compounded GLP-1s and brand-name FDA-approved injections through a structured assessment, provider review, and medication flow.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueSpry +6
48
54
Dose & formulationCorsica Health +13
77
64
Clinical oversightCorsica Health +32
87
55
Labs & monitoringCorsica Health +2
54
52
FulfillmentCorsica Health +14
75
61
Contract termsEven
55
55
Corsica Health · left barSpry · right bar

The numbers

MetricCorsica HealthSpry
WeighScore66.3/10056.8/100
GradeCC
Scorecard rank#188#408
Semaglutide$249/mo (compounded)$199/mo (starting dose, compounded)
Tirzepatide$349/mo (compounded)$299/mo (starting dose, compounded)
CoverageCoverage not publishedCoverage not published
Brand-name accessYesCompounded only
Oral / sublingualInjection onlyInjection only
Corsica Health

Graded #188 · C

Strengths

  • Public pricing shown for both compounded and brand-name options — a real transparency advantage
  • $1,499/mo brand-name Wegovy/Ozempic/Mounjaro is below typical retail cash-pay
  • LegitScript Certified
  • Clear 3-step intake: Assessment, Provider Review, Receive Medication
  • $199/mo compounded semaglutide and $249/mo compounded tirzepatide (3-month plans) are competitively priced

Where it loses points

  • Legal entity name and state of incorporation not disclosed on the site
  • Pharmacy partner described only as a 'licensed compounding pharmacy,' not named
  • Per-state availability not listed publicly
  • First-month promotional pricing not disclosed
  • Lab-work inclusion not clearly disclosed
Spry

Graded #408 · C

Strengths

  • Three named co-founders disclosed (Gabriel Mullins, Sara Yoder, Tyler Bowman) — better-than-average transparency
  • Pricing shown on the homepage ($199 semaglutide / $299 tirzepatide / $249–$299 peptides) — no full sign-up wall
  • Broader range (2 GLP-1s plus 3 anti-aging peptides) appeals to longevity buyers
  • No contracts or commitment required
  • LegitScript Certified with a public verification link

Where it loses points

  • Displays an "FDA Approved" badge though compounded GLP-1s are not FDA-approved finished drugs — potentially misleading
  • Intake reviewed by a nurse practitioner, not an MD
  • States served not disclosed publicly
  • Pharmacy partner not named, and 503A vs 503B designation not specified
  • FDA has issued this company a warning letter; the letter is public in FDA's warning-letter database

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard